[go: up one dir, main page]

CA2251353C - Dispositif pour administration transdermique de composes d'azapirone - Google Patents

Dispositif pour administration transdermique de composes d'azapirone Download PDF

Info

Publication number
CA2251353C
CA2251353C CA002251353A CA2251353A CA2251353C CA 2251353 C CA2251353 C CA 2251353C CA 002251353 A CA002251353 A CA 002251353A CA 2251353 A CA2251353 A CA 2251353A CA 2251353 C CA2251353 C CA 2251353C
Authority
CA
Canada
Prior art keywords
buspirone
azapirone
transdermal
adhesive
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002251353A
Other languages
English (en)
Other versions
CA2251353A1 (fr
Inventor
Cheryl M. Gentile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveva Drug Deliverty Systems Inc
Original Assignee
Aveva Drug Deliverty Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveva Drug Deliverty Systems Inc filed Critical Aveva Drug Deliverty Systems Inc
Priority to CA002251353A priority Critical patent/CA2251353C/fr
Priority to PCT/US1996/004745 priority patent/WO1997037659A1/fr
Priority to EP96912595A priority patent/EP0942727A1/fr
Priority to AU55363/96A priority patent/AU5536396A/en
Publication of CA2251353A1 publication Critical patent/CA2251353A1/fr
Application granted granted Critical
Publication of CA2251353C publication Critical patent/CA2251353C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un dispositif transdermique pour l'azapirone permettant d'administrer des quantités thérapeutiquement efficaces d'azapirone dans le sang, à des taux contrôlés pendant une période prolongée. L'invention est un dispositif transdermique comprenant un azapirone et un agent stabilisant servant à empêcher la recristallisation de l'azapirone à l'intérieur du dispositif transdermique.
CA002251353A 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone Expired - Fee Related CA2251353C (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002251353A CA2251353C (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
PCT/US1996/004745 WO1997037659A1 (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
EP96912595A EP0942727A1 (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
AU55363/96A AU5536396A (en) 1996-04-08 1996-04-08 Transdermal delivery device for azapirone compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002251353A CA2251353C (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
PCT/US1996/004745 WO1997037659A1 (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone

Publications (2)

Publication Number Publication Date
CA2251353A1 CA2251353A1 (fr) 1997-10-16
CA2251353C true CA2251353C (fr) 2008-10-07

Family

ID=25680592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251353A Expired - Fee Related CA2251353C (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone

Country Status (3)

Country Link
EP (1) EP0942727A1 (fr)
CA (1) CA2251353C (fr)
WO (1) WO1997037659A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0306859D0 (en) * 2003-03-25 2003-04-30 Arachnova Therapeutics Ltd Topical formulation and use of buspirone
JP6180520B2 (ja) * 2012-07-05 2017-08-16 エスケー ケミカルス カンパニー リミテッド ロチゴチンを含有した経皮吸収製剤（Ｔｒａｎｓｄｅｒｍａｌｃｏｍｐｏｓｉｔｉｏｎｃｏｍｐｒｉｓｉｎｇｒｏｔｉｇｏｔｉｎｅ）

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91451A0 (en) * 1988-08-30 1990-04-29 Bristol Myers Co Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
DE69127205T2 (de) * 1990-11-28 1998-03-05 Sano Corp., Pembroke Pines, Fla. Vorrichtung zum behandeln von tabakabhängigkeit
ES2201074T3 (es) * 1993-03-26 2004-03-16 Beth Israel Hospital Association Utilizacion topica o sistemica de buspirona o de derivados de esta para el tratamiento de trastornos patologicos asociados con reacciones inmunitarias.
WO1995001167A2 (fr) * 1993-06-25 1995-01-12 Alza Corporation Incorporation d'un amide poly-n-vinylique a un systeme transdermique

Also Published As

Publication number Publication date
CA2251353A1 (fr) 1997-10-16
WO1997037659A1 (fr) 1997-10-16
EP0942727A1 (fr) 1999-09-22

Similar Documents

Publication Publication Date Title
US5817331A (en) Transdermal administration of azapirones
EP0413487B1 (fr) Méthode et dispositif pour l'administration transdermique de dexmédétomidine
JPH0834733A (ja) 記憶障害の経皮治療製剤
KR101601335B1 (ko) 경피 흡수 제제
RU2251413C2 (ru) Трансдермальная терапевтическая система (ттс), содержащая толтеродин
US4765985A (en) Devices and methods for treating memory impairment
AU3853089A (en) Laminated composite for transdermal administration of fentanyl
TWI742628B (zh) 一種阿哌沙班透皮釋放系統及其使用方法
BRPI0713104A2 (pt) preparação de fita.
EP1503743B1 (fr) Systeme d'administration transdermique comportant deux couches adhesives superposees ayant des affinites differentes par rapport a la substance active contenue
NZ244065A (en) Laminated composite for transdermal application of benzodiazepine
CZ287373B6 (en) Transdermal therapeutic system
JP2002509879A (ja) 水分により活性化可能な治療システム
EP0831810A1 (fr) Formulation transdermique a base de ropinirole
WO2004028515A1 (fr) Timbre de type matriciel pour administration transdermique d'un analogue de la vitamine d et utilisation de ce dernier
WO2009026135A2 (fr) Système d'administration transdermique commandée de bisoprolol
EP0301589B1 (fr) Système pour l'administration transdermique du procatèrol
CA2251353C (fr) Dispositif pour administration transdermique de composes d'azapirone
US9259397B2 (en) Loratadine transdermal device and methods
US20030072791A1 (en) Felodipine transdermal device and methods
CA2038969A1 (fr) Composes contenant un agent cytotoxique et des stimulateurs de la permeation
US20040219191A1 (en) Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means
EP1328273B1 (fr) Dispositif et procedes d'administration transdermique de felodipine
EP2537534B1 (fr) Esters d'acide (1S,9S)-9-[[(1S)-1-carboxy-3-phénylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazépine-1-carboxylique et leur utilisation thérapeutique
KR100272043B1 (ko) 알쯔하이머성 치매치료용 경피흡수제제

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed